Camilla S Graham MD
Assistant Clinical Professor, Medicine, Beth Israel Deaconess Medical Center
Join to View Full Profile
330 Brookline Ave# BethBoston, MA 02215
Phone+1 617-632-7706
Dr. Graham is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Infectious Disease, 1998 - 2001
Boston University Medical CenterResidency, Internal Medicine, 1994 - 1997
MCP-Hahnemann College of MedicineClass of 1994
Certifications & Licensure
MA State Medical License 1996 - 2027
American Board of Internal Medicine Infectious Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Online Medical Record, Beth Israel Deaconess Medical Center, 2012-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification Online Medical Record, Beth Israel Deaconess Medical Center, 2012-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification Quality Data Center, Massachusetts eHealth Collaborative (MAeHC), 2012-2014, 2016-2017
Publications & Presentations
PubMed
- Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low-Level Viraemia.Paul Y Kwo, Laura E Telep, Lai San Hong, Ching Yi Chuo, Betty Chiang
Alimentary Pharmacology & Therapeutics. 2026-04-01 - 1 citationsSexual health and young people living with chronic hepatitis B: adopting a treatment as prevention framework.Suzanne J Block, Peter Daniel Block, Camilla S Graham, Mark Sulkowski, Su Wang
The Lancet. Gastroenterology & Hepatology. 2025-07-01 - 1 citationsPerspectives of people living with idiopathic pulmonary fibrosis: a qualitative and quantitative study.Camilla S Graham, Brianna Bisson, Jessica Shore, Emily Pardy, Frank Salisbury
BMC Pulmonary Medicine. 2025-05-08
Press Mentions
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated GroupOctober 22nd, 2025- PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPFAugust 21st, 2025
- PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPFAugust 21st, 2025
Grant Support
- Cellular Immunity To Hepatitis C Virus In HIVNational Institute On Drug Abuse2001–2005
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
